Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis

In multiple sclerosis, impact of treatment on disability progression can be confounded if treatment also reduces relapses. To distinguish siponimod's direct effects on disability progression from those on relapses in the EXPAND phase 3 trial. Three estimands, one based on principal stratum and...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Multiple sclerosis Ročník 27; číslo 10; s. 1564
Hlavní autoři: Cree, Bruce Ac, Magnusson, Baldur, Rouyrre, Nicolas, Fox, Robert J, Giovannoni, Gavin, Vermersch, Patrick, Bar-Or, Amit, Gold, Ralf, Piani Meier, Daniela, Karlsson, Göril, Tomic, Davorka, Wolf, Christian, Dahlke, Frank, Kappos, Ludwig
Médium: Journal Article
Jazyk:angličtina
Vydáno: England 01.09.2021
Témata:
Azetidines - therapeutic use
Benzyl Compounds - therapeutic use
Disease Progression
Humans
Multiple Sclerosis, Chronic Progressive - drug therapy
Recurrence
progression
Multiple sclerosis
relapses
secondary progressive multiple sclerosis
progressive multiple sclerosis
siponimod
ISSN:1477-0970, 1477-0970
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:In multiple sclerosis, impact of treatment on disability progression can be confounded if treatment also reduces relapses. To distinguish siponimod's direct effects on disability progression from those on relapses in the EXPAND phase 3 trial. Three estimands, one based on principal stratum and two on hypothetical scenarios (no relapses, or equal relapses in both treatment arms), were defined to determine the extent to which siponimod's effects on 3- and 6-month confirmed disability progression were independent of on-study relapses. Principal stratum analysis estimated that siponimod reduced the risk of 3- and 6-month confirmed disability progression by 14%-20% and 29%-33%, respectively, compared with placebo in non-relapsing patients. In the hypothetical scenarios, risk reductions independent of relapses were 14%-18% and 23% for 3- and 6-month confirmed disability progression, respectively. By controlling the confounding impact of on-study relapses on confirmed disability progression, these statistical approaches provide a methodological framework to assess treatment effects on disability progression in relapsing and non-relapsing patients. The analyses support that siponimod may be useful for treating secondary progressive multiple sclerosis in patients with or without relapses.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:1477-0970
1477-0970
DOI:10.1177/1352458520971819